Too early to celebrate? Alzheimer’s drug trial success leaves questions
By
Alicia Lasek
Sep 30, 2022
News that Alzheimer’s drug lecanemab has reduced cognitive decline by 27% is receiving measured responses from prescribers as they await further data.
Tonko, LaHood urge HHS to expand access to Aduhelm, similar Alzheimer’s drugs
By
Alicia Lasek
Feb 08, 2022
The Medicare coverage proposal for these drugs is too restrictive, limiting potential benefits to a select few, the two congressmen argue in a letter sent Monday to HHS Secretary Xavier Becerra.
CMS will reveal intent to cover Alzheimer’s drug — or not — tomorrow
By
Amy Novotney
Jan 11, 2022
U.S. Secretary of Health and Human Services Xavier Becerra on Monday ordered Medicare to reassess a big premium increase facing millions of seniors this year, after an expensive new Alzheimer’s drug...
Trial begins of nasal vaccine for Alzheimer disease
Nov 18, 2021
Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health
First human trial of nasal vaccine for Alzheimer’s set to begin in Boston
By
Alicia Lasek
Nov 18, 2021
Sixteen participants with early, symptomatic Alzheimer’s will receive doses of a vaccine containing the immune-modulating drug Protollin. Nasal delivery has shown promise as a way to eliminate beta amyloid...
Clinical briefs for Wednesday, Nov. 10
By
Alicia Lasek
Nov 10, 2021
Legal challenges aside, senior living operators advised to prepare for COVID-19 vaccine mandate … Patient treated with Alzheimer’s drug aducanumab has six brain abnormality episodes … Feds invest...
Drugmakers ask FDA to approve another Alzheimer’s drug, similar to Aduhelm
By
Alicia Lasek
Sep 29, 2021
Drugmakers Eisai and Biogen are putting the Food and Drug Administration to the test with a request to approve a second Alzheimer’s drug that works like aducanumab (Aduhelm), the new, yet controversial,...
U.S. lawmakers ramp up scrutiny of FDA following agency’s approval of controversial Alzheimer’s drug
By
Alicia Lasek
Sep 07, 2021
The FDA is being asked to help explain how Aduhelm (aducanumab) met accelerated approval criteria when so many experts — including internal advisers — have flagged insufficient safety and efficacy...
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
First appropriate use guidance published for Alzheimer’s drug Aduhelm
By
Alicia Lasek
Jul 28, 2021
The new guidelines cover how to choose appropriate patients, safely scale up to a full dose, monitor side effects and assess effectiveness. The authors also address when to stop therapy and what patients...